Outcomes of Acromegaly Patients Treated with Sandostatin LAR after Surgical Excision of Pituitary Adenoma


  • Sumira Kiran
  • Muhammad Kaleem Iftikhar
  • Muhammad Naveed Majeed Punjab Institute of Neurosciences
  • Ch. Arslan Ahmad
  • Khawar Anwar
  • Asif Bashir




Acromegaly, Macroadenoma, Growth Hormone, Insulin like growth factor - 1


Objectives:  An observational study to evaluate the outcomes of Acromegaly patients treated in the department of Neurosurgery III, Punjab Institute of Neurosciences (PINS), Lahore, Pakistan.

Materials and Methods:  This study was the analysis of a case series of 20 patients (mean age: 30 years) of both genders with acromegaly due to macroadenoma who had endonasal excision and postoperative treatment with Sandostatin LAR.

Results:  This study consisted of a total of 20 patients out of which 11 (55%) were male and 9 (45%) were female. All 20 Patients (100%) had a headache as their main symptom and 13 patients (65%) had visual field deterioration. 19 patients (95%) had complete resection of the tumor whereas 1 (5%) had a subtotal resection. After surgery and treatment growth hormone levels improved in 19 patients (95%) and remained elevated in 1 patient (5%), IGF-1 (Insulin-like growth factor – 1) levels improved in all 20 (100%) patients. Following consecutive octreotide injections vision of 11 patients (84%) out of 13 improved and in 2 (16%) patients, it remained the same as of Preoperative status whereas Headache improved in all 20 (100%) of the patients. None of the patients had any complications related to the procedure or the injection of octreotide LAR.

Conclusion:  Acromegaly due to macroadenoma responds well to treatment with octreotide LAR after endonasal resection in terms of hormonal levels and symptoms of the patients. It is a safe treatment with very less side effects and complications.


Jagannathan J, Dumont AS, Prevedello DM, Lopes B, Oskouian RJ, Jane Jr JA, et al. Genetics of pituitary adenomas: current theories and future implications. Neurosurg Focus. 2005;19(5):E4.

Melmed S. Acromegaly. New England Journal of Medicine. 2006;355(24):2558-73.

Petrossians P, Daly AF, Natchev E, Maione L, Blijdorp K, Sahnoun-Fathallah M, et al. Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database. Endocrine-related cancer. 2017;24(10):505-18.

Colao A, Grasso LF, Giustina A, Melmed S, Chanson P, Pereira AM, et al. Acromegaly. Nature Reviews Disease Primers. 2019;5(1):1-17.

BENGTSSON BÅ, EDÉN S, ERNEST I, ODÉN A, SJÖGREN B. Epidemiology and long?term survival in acromegaly: a study of 166 cases diagnosed between 1955 and 1984. Acta Medica Scandinavica. 1988;223(4):327-35.

Agustsson TT, Baldvinsdottir T, Jonasson JG, Olafsdottir E, Steinthorsdottir V, Sigurdsson G, et al. The epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study. Eur J Endocrinol. 2015;173(5):655-64.

Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. The Journal of Clinical Endocrinology & Metabolism. 2006;91(12):4769-75.

Grynberg Ml, Salenave S, Young J, Chanson P. Female gonadal function before and after treatment of acromegaly. The Journal of Clinical Endocrinology & Metabolism. 2010;95(10):4518-25.

Katznelson L, Laws Jr ER, Melmed S, Molitch ME, Murad MH, Utz A, et al. Acromegaly: an endocrine society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2014;99(11):3933-51.

Jaffe CA, Barkan AL. Acromegaly. Drugs. 1994;47(3):425-45.

Lamberts SW, Van der Lely A-J, de Herder WW, Hofland LJ. Octreotide. new england Journal of Medicine. 1996;334(4):246-54.

Fahlbusch R, Kleinberg D, Biller B, Bonert V, Buchfelder M, Cappabianca P, et al. Surgical debulking of pituitary adenomas improves responsiveness to octreotide lar in the treatment of acromegaly. Pituitary. 2017;20(6):668-75.

Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘cure’. European Journal of Endocrinology. 2005;152(3):379-87.

Freda PU, Wardlaw SL, Post KD. Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. Journal of Neurosurgery. 1998;89(3):353-8.

Racine MS, Barkan AL. Medical management of growth hormone-secreting pituitary adenomas. Pituitary. 2002;5(2):67-76.

Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, et al. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. The Journal of Clinical Endocrinology & Metabolism. 2005;90(7):4405-10.






Original Articles